FANCI, CPTAC-3283 - CPTAC Assay Portal (original) (raw)
Please include the following statement when referencing the CPTAC Assay Portal
We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.
Protein Sequence hover to view complete sequence
| 10 | 20 | 30 | 40 | 50 |
|---|---|---|---|---|
| MDQKILSLAA | EKTADKLQEF | LQTLREGDLT | NLLQNQAVKG | KVAGALLRAI |
| 60 | 70 | 80 | 90 | 100 |
| FKGSPCSEEA | GTLRRRKIYT | CCIQLVESGD | LQKEIASEII | GLLMLEAHHF |
| 110 | 120 | 130 | 140 | 150 |
| PGPLLVELAN | EFISAVREGS | LVNGKSLELL | PIILTALATK | KENLAYGKGV |
| 160 | 170 | 180 | 190 | 200 |
| LSGEECKKQL | INTLCSGRWD | QQYVIQLTSM | FKDVPLTAEE | VEFVVEKALS |
| 210 | 220 | 230 | 240 | 250 |
| MFSKMNLQEI | PPLVYQLLVL | SSKGSRKSVL | EGIIAFFSAL | DKQHNEEQSG |
| 260 | 270 | 280 | 290 | 300 |
| DELLDVVTVP | SGELRHVEGT | IILHIVFAIK | LDYELGRELV | KHLKVGQQGD |
| 310 | 320 | 330 | 340 | 350 |
| SNNNLSPFSI | ALLLSVTRIQ | RFQDQVLDLL | KTSVVKSFKD | LQLLQGSKFL |
| 360 | 370 | 380 | 390 | 400 |
| QNLVPHRSYV | STMILEVVKN | SVHSWDHVTQ | GLVELGFILM | DSYGPKKVLD |
| 410 | 420 | 430 | 440 | 450 |
| GKTIETSPSL | SRMPNQHACK | LGANILLETF | KIHEMIRQEI | LEQVLNRVVT |
| 460 | 470 | 480 | 490 | 500 |
| RASSPISHFL | DLLSNIVMYA | PLVLQSCSSK | VTEAFDYLSF | LPLQTVQRLL |
| 510 | 520 | 530 | 540 | 550 |
| KAVQPLLKVS | MSMRDCLILV | LRKAMFANQL | DARKSAVAGF | LLLLKNFKVL |
| 560 | 570 | 580 | 590 | 600 |
| GSLSSSQCSQ | SLSVSQVHVD | VHSHYNSVAN | ETFCLEIMDS | LRRCLSQQAD |
| 610 | 620 | 630 | 640 | 650 |
| VRLMLYEGFY | DVLRRNSQLA | NSVMQTLLSQ | LKQFYEPKPD | LLPPLKLEAC |
| 660 | 670 | 680 | 690 | 700 |
| ILTQGDKISL | QEPLDYLLCC | IQHCLAWYKN | TVIPLQQGEE | EEEEEEAFYE |
| 710 | 720 | 730 | 740 | 750 |
| DLDDILESIT | NRMIKSELED | FELDKSADFS | QSTSIGIKNN | ICAFLVMGVC |
| 760 | 770 | 780 | 790 | 800 |
| EVLIEYNFSI | SSFSKNRFED | ILSLFMCYKK | LSDILNEKAG | KAKTKMANKT |
| 810 | 820 | 830 | 840 | 850 |
| SDSLLSMKFV | SSLLTALFRD | SIQSHQESLS | VLRSSNEFMR | YAVNVALQKV |
| 860 | 870 | 880 | 890 | 900 |
| QQLKETGHVS | GPDGQNPEKI | FQNLCDITRV | LLWRYTSIPT | SVEESGKKEK |
| 910 | 920 | 930 | 940 | 950 |
| GKSISLLCLE | GLQKIFSAVQ | QFYQPKIQQF | LRALDVTDKE | GEEREDADVS |
| 960 | 970 | 980 | 990 | 1000 |
| VTQRTAFQIR | QFQRSLLNLL | SSQEEDFNSK | EALLLVTVLT | SLSKLLEPSS |
| 1010 | 1020 | 1030 | 1040 | 1050 |
| PQFVQMLSWT | SKICKENSRE | DALFCKSLMN | LLFSLHVSYK | SPVILLRDLS |
| 1060 | 1070 | 1080 | 1090 | 1100 |
| QDIHGHLGDI | DQDVEVEKTN | HFAIVNLRTA | APTVCLLVLS | QAEKVLEEVD |
| 1110 | 1120 | 1130 | 1140 | 1150 |
| WLITKLKGQV | SQETLSEEAS | SQATLPNQPV | EKAIIMQLGT | LLTFFHELVQ |
| 1160 | 1170 | 1180 | 1190 | 1200 |
| TALPSGSCVD | TLLKDLCKMY | TTLTALVRYY | LQVCQSSGGI | PKNMEKLVKL |
| 1210 | 1220 | 1230 | 1240 | 1250 |
| SGSHLTPLCY | SFISYVQNKS | KSLNYTGEKK | EKPAAVATAM | ARVLRETKPI |
| 1260 | 1270 | 1280 | 1290 | 1300 |
| PNLIFAIEQY | EKFLIHLSKK | SKVNLMQHMK | LSTSRDFKIK | GNILDMVLRE |
| 1310 | 1320 | 1328 | ||
| DGEDENEEGT | ASEHGGQNKE | PAKKKRKK |
Data source: UniProt
Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs
Uniprot Database Entry PhosphoSitePlus ®
Click a point on a node
to view detailed assay information below
All other points link out to UniProt
Phosphorylation Acetylation Ubiquitylation Other
loading
Assay Details for CPTAC-3283 Collapse assay details
Data source: Panorama
Official Gene Symbol
FANCI
Peptide Modified Sequence
SADFS[+80.0]QSTSIGIK
Modification Type
Phospho (ST)
Protein - Site of Modification
730
Peptide - Site of Modification
5
Peptide Start
726
Peptide End
738
CPTAC ID
CPTAC-3283
Peptide Molecular Mass
1,419.6283
Species
Homo sapiens (Human)
Assay Type
Enrichment ImmunoMRM
Enrichment Method
peptide immunoaffinity
Matrix
cell lysate
Submitting Laboratory
Fred Hutchinson Cancer Research Center
Submitting Lab PI
Amanda Paulovich
Publication
View Details (opens in a new window)
A Multiplexed Mass Spectrometry-Based Assay for Robust Quantification of Phosphosignaling in Response to DNA Damage. Whiteaker JR, Zhao L, Saul R, Kaczmarczyk JA, Schoenherr RM, Moore HD, Jones-Weinert C, Ivey RG, Lin C, Hiltke T, Reding KW, Whiteley G, Wang P, Paulovich AG. Radiat Res. 2018 Feb 23. doi: 10.1667/RR14963.1. [Epub ahead of print]
Assay Parameters Collapse assay parameters
Data source: Panorama
Instrument
6500 QTRAP (Sciex)
Internal Standard
synthetic peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
Ultra NanoLC 2D+ (Eksigent)
Column Packing
ReproSil-Pur C18-AQ 3um
Column Dimensions
100 x 0.075 mm
Flow Rate
300 uL/min
Chromatograms
Data source: Panorama
Response Curves
Data source: Panorama
Retrieving Data
Repeatability
Data source: Panorama
| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CV
| n= | | | | | | | | | |
| ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- |
| Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
| y9-98 (2+) | 53.3 | 26.7 | 36.9 | 68.6 | 40.6 | 30.3 | 86.9 | 48.6 | 47.7 | 15 | 15 | 15 |
| y10-98 (2+) | 55.6 | 36.1 | 22 | 96.5 | 49.9 | 24.7 | 111.4 | 61.6 | 33.1 | 15 | 15 | 15 |
| y9-98 (1+) | 60 | 20.6 | 35.9 | 104.4 | 49.4 | 54.8 | 120.4 | 53.5 | 65.5 | 15 | 15 | 15 |
| y9 (1+) | 47.1 | 32.5 | 17.9 | 64 | 39.2 | 19.7 | 79.5 | 50.9 | 26.6 | 15 | 15 | 15 |
| y10-98 (1+) | 56.8 | 32.2 | 19.1 | 97.5 | 39.9 | 19.3 | 112.8 | 51.3 | 27.2 | 14 | 15 | 15 |
| sum | 24.2 | 11.7 | 19.4 | 39 | 22.8 | 26.1 | 45.9 | 25.6 | 32.5 | 15 | 15 | 15 |